1 min read

In my time at Vertex, I have seen our team of scientists and researchers make great strides in our development of treatment options for the underlying cause of cystic fibrosis (CF), a rare, chronic and life-shortening genetic disease.

This journey first began more than 20 years ago in Vertex’s labs.

While addressing the dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein with a small molecule approach was deemed impossible by many, our commitment to helping patients with this devastating disease was unwavering.

Today, we have four medicines available to certain eligible people with CF.

But we won’t stop there. 

While our current portfolio of therapies has the ability to treat up to 90% of people living with CF, we are devoted to reaching every person with the disease. We have set the bar high for ourselves, and I’ve remained amazed by the grit and tenacity our team brings each and every day to innovate, discover and test additional investigational medicines and combination therapies.

For example, we are partnering with Moderna on an investigational new type of messenger ribonucleic acid, or mRNA, therapy that we hope may help to treat the approximately 5,000 people who have no treatment options for the underlying cause of their disease.

To learn more about our journey in CF and our commitment to innovative science, watch this short video.